Infertility
Conditions
Keywords
IVF, genetic screening, preimplantation genetic testing
Brief summary
In this study, study investigators will collect embryo culture media on day 5 of vitro fertilization (IVF) culture, prior to vitrification and embryo transfer for testing via Metabolomic screening. Metabolomics is a new, non-invasive method of embryo selection which involves testing discarded embryo culture media for analytes secreted by the developing embryo. These analytes can be used to determine the implantation potential, and ploidy, of the embryo.
Detailed description
Patients will undergo a routine IVF cycle. This will include ovarian stimulation, egg retrieval and fertilization of oocytes through intracytoplasmic sperm injection (ICSI). All fertilized oocytes will be cultured up to blastocyst for five to six days. Spent media will be collected on day 5-6 for all embryos reaching blastocyst on day 5, and on day 6 for those reaching blastocyst on day 6. The spent culture media will be sent to a lab for metabolomic analysis. For the embryo transfer, the best morphology blastocyst will be selected for transfer by the New Hope embryologist. Approximately 8-11 days after the embryo transfer, the patient will return to the clinic for a serum pregnancy test. Should the test be negative, they will be closed out of the study. Should the test be positive, they will continue to be monitored. The patient will return to the clinic at approximately 8 weeks after embryo transfer for a serum pregnancy test, and an ultrasound to detect fetal heartbeat. The outcome will be documented and the patient closed out of the study at this time. The embryo transfer outcome will be compared to the metabolomics result to determine the NPV and PPV of metabolomics vs implantation.
Interventions
DIAGNOSTIC_TESTOverture Metabolomics Embryo Selection
Patients will have their embryos selected for transfer based on morphology alone. The embryo transfer outcome will be compared to the metabolomics result to determine the NPV and PPV of metabolomics vs implantation.
Sponsors
Clinica Juana Crespo
Grupo Procrearte
Overture Life
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 38 Years
Healthy volunteers
Yes
Inclusion criteria
* Women of any age, 25% of patients \<35 years, 25% of patients 35-37, 25% of patients 38-40, and 25% of patients \>40 years. * Signed Subject Consent Form. No inferior limit on number of eggs
Exclusion criteria
At the time of initial visit: * Require or request PGT of any kind * Low ovarian reserve defined as follicle stimulating hormone (FSH) \>10 IU/L on day 2-4 of a prior menstrual cycle and anti-mullerian hormone (AMH) \<15 pmol/L (or \<2 ng/ml) within prior 12 months of cycle start At the time of embryo selection: -Patients without at least one embryo to transfer.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Negative predictive value (NPV) and positive predictive value (PPV) for MEI vs. expected implantation based solely on morphology. | Approximately 4-5 months, inclusive of IVF cycle, embryo transfer and monitoring up to eight weeks | PPV (MEI high potential implanting / Total implanting), NPV (MEI low potential implanting / Total not implanting) |
Countries
Argentina, Spain
Contacts
Primary ContactAlexander Nadal
Backup ContactSara Cabello
Outcome results
None listed